Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Adrienne Williams

Obstetrics & Gynecology West Monroe, LA Medical Doctor

NPI 1760486567 CMS profile 641394

417 McMillan Rd, West Monroe, LA 71291

Open in the dashboard

General payments

$6,521

180 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adrienne Williams of West Monroe, LA is reported in the CMS Open Payments database as having received $6,521 across 180 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $521 15
2024 General $381 15
2023 General $680 21
2022 General $3,462 54
2021 General $684 28
2020 General $344 19
2019 General $449 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adrienne Williams
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Adrienne Williams were reported at $521. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Adrienne Williams Obstetrics & Gynecology median Middle half National median
2019 $449 $172 $62–$391 $163
2020 $344 $94 $36–$222 $114
2021 $684 $136 $42–$369 $132
2022 $3,462 $160 $50–$433 $149
2023 $680 $169 $56–$423 $160
2024 $381 $152 $50–$371 $164
2025 $521 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Axonics Modulation Technologies, Inc. $1,977 11 payments
  2. Medtronic, Inc. $1,008 9 payments
  3. Amgen Inc. $710 24 payments
  4. Astellas Pharma US Inc $488 23 payments
  5. AbbVie, Inc. $430 24 payments
  6. Mayne Pharma Inc. $382 6 payments
  7. Pfizer Inc. $354 23 payments
  8. Daiichi Sankyo Inc. $188 9 payments
  9. Sumitomo Pharma America, Inc. $169 4 payments
  10. Evofem Biosciences, Inc. $164 10 payments
  11. Other $651 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,959 172 payments
  2. Travel and Lodging $2,476 7 payments
  3. Education $85 1 payment
Products named General payments · program years 2019–2025
  1. Bulkamid $1,831 9 payments
  2. Axonics $1,802 7 payments
  3. INTERSTIM $1,008 9 payments
  4. EVENITY $560 21 payments
  5. Prolia $384 19 payments
  6. Veozah $326 17 payments
  7. ORILISSA $208 12 payments
  8. LO LOESTRIN FE $193 12 payments
  9. PREMARIN $184 13 payments
  10. MYFEMBREE $167 10 payments
  11. Other $1,796 84 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

711

Median for Obstetrics & Gynecology: 65

Drug cost

$38,138

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

34.5%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Premarin Estrogens, Conjugated Brand 34 $9,657
Estradiol Generic 185 $6,933
Imiquimod Generic 25 $3,933
Prempro Estrogen,con/M-Progest Acet Brand 13 $3,060
Osphena Ospemifene Brand 11 $2,531
Raloxifene Hcl Generic 71 $2,128
Estradiol-Norethindrone Acetat Estradiol/Norethindrone Acet Brand 28 $1,490
Estradiol (Twice Weekly) Estradiol Brand 18 $1,303
Metronidazole Generic 28 $1,138
Estradiol (Once Weekly) Estradiol Brand 26 $1,046

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$33,116

Medicare's payments for the services billed

Medicare patients

262

Average age 73

Services billed

605

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 46%
Osteoporosis 28%
Diabetes 22%
Ischemic heart disease 18%
Cancer 15%
Chronic kidney disease 14%
Atrial fibrillation 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $115
$115 — —
EVENITY
  • Amgen Inc. $79
$79 — —
PYLARIFY
  • Progenics Pharmaceuticals, Inc. $17
$17 — —
DUAVEE
  • PFIZER INC. $7
$7 — —
PREMARIN
  • PFIZER INC. $7
$7 34 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

180 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record